Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![25_08_Cell&GeneThePodcast_1280x720_FF_Ep02]( "Navigating Regulatory Complexity In Cell And Gene Therapy")
Navigating Regulatory Complexity In Cell And Gene Therapy8/26/2025This is a recap of the first three episodes of FDA Fridays, a special four-week series from Cell & Gene: The Podcast. These conversations shed light on the current challenges, best practices, and forward-looking strategies shaping the CGT regulatory environment.
-
![Medical research-GettyImages-1287846309]( "Accelerating NAMs For A Human-Based Future In CGT Development")
Accelerating NAMs For A Human-Based Future In CGT Development8/1/2025The Complement-ARIE Consortium, led by FNIH’s Stacey Adam, Ph.D., is advancing the development, validation, and regulatory adoption of human-based new approach methodologies (NAMs) to transform preclinical testing and accelerate cell and gene therapy development.
-
![Natural killer cell attacking cancer cell-GettyImages-1389774283]( "Navigating The Complexities Of NK Cell Therapy Development")
Navigating The Complexities Of NK Cell Therapy Development7/30/2025Deloitte's Amit Agarwal and Ashraf Husain share expert insights on how NK cell therapy developers can overcome manufacturing, supply chain, and commercialization challenges to successfully scale these promising therapies.
-
![Extracellular vesicles EVs-GettyImages-2009511436]( "Redefining CGT With Exosomes And EVs")
Redefining CGT With Exosomes And EVs7/16/2025July’s Cell & Gene Live featured a comprehensive look at the scientific advances, clinical promise, manufacturing hurdles, and regulatory considerations shaping extracellular vesicle and exosome-based therapies.
-
![neurological diseases, stroke, cancer, tumor-GettyImages-864745624]( "Inside AviadoBio And Astellas's Shared Mission To Bring Gene Therapy To Patients With FTD-GRN")
Inside AviadoBio And Astellas's Shared Mission To Bring Gene Therapy To Patients With FTD-GRN7/2/2025AviadoBio and Astellas have joined forces to advance an investigational gene therapy designed to treat frontotemporal dementia with progranulin mutations (FTD-GRN), aiming to address a critical unmet need in neurodegenerative disease.
-
![25_06_CGL_450x300]( "Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More")
Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More6/24/2025During this month’s Cell and Gene Live, Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More, expert panelists Francesca Barone, M.D., Ph.D., CSO at Candel Therapeutics and Karen Kozarsky, Ph.D., President of Vector BioPartners shared their perspectives on current challenges, technological innovations, and future directions in gene therapy vector development and application.
-
![Medical Student Textbooks-GettyImages-921644532]( "Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham")
Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham6/23/2025The RISE framework — focused on Resource sharing, Interdisciplinary collaboration, Sustainable funding, and Educational outreach — is helping academic medical centers such as Mass General Brigham overcome translational barriers in cell and gene therapy development and bring promising therapies closer to clinical application.
-
![Research laboratory microscope-GettyImages-1564542843]( "The Promise Of Focused Ultrasound For AAV Gene Therapy Delivery")
The Promise Of Focused Ultrasound For AAV Gene Therapy Delivery6/11/2025Dr. Bernie Owusu-Yaw, a research fellow at Brigham and Women’s Hospital and Harvard Medical School, is pioneering a promising gene therapy approach that combines focused ultrasound with novel AAV capsids to safely and effectively deliver therapeutics across the blood-brain barrier, offering new hope for treating challenging neurodegenerative diseases.
-
![multiple Induced Pluripotent Stem Cells - iPSCs GettyImages-1368249640]( "Unlocking The Potential Of iPSC Therapies In Regenerative Medicine")
Unlocking The Potential Of iPSC Therapies In Regenerative Medicine5/21/2025In a recent Cell & Gene Live, leaders from Mayo Clinic and Astellas discussed the transformative potential of iPSC therapies in regenerative medicine, highlighting regulatory alignment and manufacturing innovation to realize their full impact.
-
![scientist with microscope-GettyImages-1181392325]( "Ferring Builds A Global Gene Therapy Manufacturing Network Around ADSTILADRIN")
Ferring Builds A Global Gene Therapy Manufacturing Network Around ADSTILADRIN5/16/2025Ferring Pharmaceuticals has built a global manufacturing and support network around its flagship gene therapy, ADSTILADRIN, enabling scalable production, provider education, patient access, and real-world data collection to ensure sustainable and widespread adoption.
